Evidence map›Paper›PMID 33805778›Full record

ArticleInternational journal of molecular sciences2021

Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation.

Pratishtha Chatterjee, Michelle Tegg, Steve Pedrini, Anne M Fagan, Chengjie Xiong, Abhay K Singh, Kevin Taddei, Samantha Gardener, Colin L Masters, Peter R Schofield and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Review
  9. Review
  10. Fluid biomarkers in cerebral amyloid angiopathy.Frontiers in neuroscience · 2024
    Review
  11. Review
  12. Article
  13. Molecular Mechanisms of Alzheimer's Disease III.International journal of molecular sciences · 2022
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 4 countries.

Pratishtha ChatterjeeDepartment of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Michelle TeggSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.
Steve PedriniSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-6409-8022
Anne M FaganDepartment of Neurology, Washington University, St. Louis, MO 63130, USA.
Chengjie XiongKnight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63130, USA.
Abhay K SinghMacquarie Business School, Macquarie University, North Ryde, NSW 2109, Australia.
Kevin TaddeiSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-8106-7957
Samantha GardenerSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-1933-5260
Colin L MastersThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia.
Peter R SchofieldNeuroscience Research Australia, Sydney, NSW 2031, Australia.ORCID 0000-0003-2967-9662
Gerhard MulthaupDepartment of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada.
Tammie L S BenzingerKnight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63130, USA.
John C MorrisDepartment of Neurology, Washington University, St. Louis, MO 63130, USA.
Randall J BatemanDepartment of Neurology, Washington University, St. Louis, MO 63130, USA.
Steven M GreenbergDepartment of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, MA 02114, USA.
Mark A van BuchemDepartment of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Erik StoopsADx NeuroSciences, 9052 Gent, Belgium.
Hugo VandersticheleBiomarkable, 9000 Gent, Belgium.
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, 1007 MB Amsterdam, The Netherlands.
Graeme J HankeyFaculty of Health and Medical Sciences, Medical School, The University of Western Australia, Crawley, WA 6009, Australia.
Marieke J H WermerDepartment of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Hamid R SohrabiDepartment of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Ralph N MartinsDepartment of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
The Dominantly Inherited Alzheimer Network
Edith Cowan University · AUWashington University in St. Louis · USLeiden University Medical Center · NLADx NeuroSciencesAmsterdam Neuroscience · NLHarvard University · USMacquarie University · AUMcGill University · CAThe University of Melbourne · AUThe University of Western Australia · AUUNSW Sydney · AU

Funding

Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
National Health and Medical Research Council APP1129627NIA NIH HHS U19 AG032438NIH HHS U19AG032438
6 · The paper itself

Abstract

Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which could be attributed to the use of less sensitive assays. This study investigates plasma Aβ alterations between pre-symptomatic Dutch-type hereditary CAA (D-CAA) mutation-carriers (MC) and non-carriers (NC) using two Aβ measurement platforms. Seventeen pre-symptomatic members of a D-CAA pedigree were assembled and followed up 3-4 years later (NC = 8; MC = 9). Plasma Aβ1-40 and Aβ1-42 were cross-sectionally and longitudinally analysed at baseline (T1) and follow-up (T2) and were found to be lower in MCs compared to NCs, cross-sectionally after adjusting for covariates, at both T1(Aβ1-40:

Indexed as

AdultAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAsymptomatic DiseasesBiomarkersCerebral Amyloid Angiopathy, FamilialDisease ProgressionFemaleGene ExpressionGenes, DominantHeterozygoteHumansLongitudinal StudiesMaleMiddle AgedMutationAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Amyloid beta-Protein PrecursorAPP protein, humanBiomarkersPeptide Fragmentsamyloid-betablood biomarkerscerebral amyloid angiopathyearly diagnosishereditary cerebral haemorrhage with amyloidosis—Dutch typeplasma amyloid-betasingle molecule array platform

Identifiers

PMID33805778
PMCPMC8000178
OpenAlexW3137631690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.